ClinicalTrials.gg

Program

FXS0683

A development code.

In Fosun Pharma's pipeline, BCL-2. Its studies are mostly in Lymphoma, B-Cell, led by Fosun Pharma.

Furthest: phase 1, since May 19, 20261 company-led study, 1 open or runningNext primary completion: Aug 7, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma11 open or runningphase 1since May 19, 2026May 19, 2026Aug 7, 2028phase 1 · NCT07616089
  • Named in Fosun Pharma’s own pipeline as FXS0683 (BCL-2), phase 1, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2026First study: phase 1 study in Lymphoma, B-CellFirst studyNCT07616089 · 228 planned · China

Ahead

  1. Aug 7, 2028Primary completion: phase 1 study in Lymphoma, B-CellNCT07616089

TargetBeta

“BCL-2”the company's pipeline, read by Claude · source

Other programs on BCL2

ProgramCompanyFurthest phaseStudies
venetoclaxruleAbbViephase 483
Bcl-2 Inhibitor TQB3909Sino Biopharmaceuticalphase 38
lacutoclaxruleLupeng Pharmaceuticalphase 24
surzetoclaxAbbViephase 23
400mg of TQB3909 tabletsSino Biopharmaceuticalphase 21
surzetoclaxAbbViephase 12

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07616089Lymphoma, B-Cell · China1RecruitingAug 7, 2028228

How it is read

Names in the registry

  • “FXS0683”, 1 entry

Codes read as this program: FXS0683.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.